{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:23:52Z","timestamp":1780395832346,"version":"3.54.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Seed Fund of Peking University First Hospital","award":["2025SF053"],"award-info":[{"award-number":["2025SF053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08011-6","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:10:00Z","timestamp":1774275000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular imaging in gastric cancer: state-of-the-art techniques and emerging opportunities"],"prefix":"10.1186","volume":"24","author":[{"given":"Kexin","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"8011_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264\u201379. https:\/\/doi.org\/10.3322\/caac.21657.","journal-title":"CA Cancer J Clin"},{"key":"8011_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"key":"8011_CR3","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.3748\/wjg.v26.i36.5408","volume":"26","author":"P-H Niu","year":"2020","unstructured":"Niu P-H, Zhao L-L, Wu H-L, Zhao D-B, Chen Y-T. Artificial intelligence in gastric cancer: Application and future perspectives. World J Gastroenterol. 2020;26:5408\u201319. https:\/\/doi.org\/10.3748\/wjg.v26.i36.5408.","journal-title":"World J Gastroenterol"},{"key":"8011_CR4","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.7150\/jca.95311","volume":"15","author":"Y Huang","year":"2024","unstructured":"Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G. Global progress and future prospects of early gastric cancer screening. J Cancer. 2024;15:3045\u201364. https:\/\/doi.org\/10.7150\/jca.95311.","journal-title":"J Cancer"},{"key":"8011_CR5","doi-asserted-by":"publisher","first-page":"778728","DOI":"10.3389\/fonc.2021.778728","volume":"11","author":"L Wen","year":"2021","unstructured":"Wen L, Xia L, Guo X, Huang H-F, Wang F, Yang X-T, et al. Multimodal imaging technology effectively monitors HER2 expression in tumors using trastuzumab-coupled organic nanoparticles in patient-derived xenograft mice models. Front Oncol. 2021;11:778728. https:\/\/doi.org\/10.3389\/fonc.2021.778728.","journal-title":"Front Oncol"},{"key":"8011_CR6","doi-asserted-by":"publisher","first-page":"1405485","DOI":"10.3389\/fimmu.2024.1405485","volume":"15","author":"D Ibrahim","year":"2024","unstructured":"Ibrahim D, Sim\u00f3 C, Brown EL, Shmuel S, Panikar SS, Benton A, et al. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET. Front Immunol. 2024;15:1405485. https:\/\/doi.org\/10.3389\/fimmu.2024.1405485.","journal-title":"Front Immunol"},{"key":"8011_CR7","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1021\/acs.molpharmaceut.4c00122","volume":"21","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma L, Kuang Z, Li D, Yang J, Liu Y, et al. Preparation of radiolabeled zolbetuximab targeting CLDN18.2 and its preliminary evaluation for potential clinical applications. Mol Pharm. 2024;21:3838\u201347. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00122.","journal-title":"Mol Pharm"},{"key":"8011_CR8","doi-asserted-by":"publisher","first-page":"20181044","DOI":"10.1259\/bjr.20181044","volume":"92","author":"AS Borggreve","year":"2019","unstructured":"Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, et al. Imaging strategies in the management of gastric cancer: Current role and future potential of MRI. Br J Radiol. 2019;92:20181044. https:\/\/doi.org\/10.1259\/bjr.20181044.","journal-title":"Br J Radiol"},{"key":"8011_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10120-008-0492-5","volume":"12","author":"RM Kwee","year":"2009","unstructured":"Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6\u201322. https:\/\/doi.org\/10.1007\/s10120-008-0492-5.","journal-title":"Gastric Cancer"},{"key":"8011_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00330-016-4442-z","volume":"27","author":"C Shi","year":"2017","unstructured":"Shi C, Zhang H, Yan J, Wang B, Du L, Pan Z, et al. Decreased stage migration rate of early gastric cancer with a new reconstruction algorithm using dual-energy CT images: A preliminary study. Eur Radiol. 2017;27:671\u201380. https:\/\/doi.org\/10.1007\/s00330-016-4442-z.","journal-title":"Eur Radiol"},{"key":"8011_CR11","doi-asserted-by":"publisher","first-page":"e232387","DOI":"10.1148\/radiol.232387","volume":"312","author":"Q Li","year":"2024","unstructured":"Li Q, Xu W-Y, Sun N-N, Feng Q-X, Zhu Z-N, Hou Y-J, et al. MRI versus dual-energy CT in local-regional staging of gastric cancer. Radiology. 2024;312:e232387. https:\/\/doi.org\/10.1148\/radiol.232387.","journal-title":"Radiology"},{"key":"8011_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12880-021-00550-2","volume":"21","author":"S De Vuysere","year":"2021","unstructured":"De Vuysere S, Vandecaveye V, De Bruecker Y, Carton S, Vermeiren K, Tollens T, et al. Accuracy of whole-body diffusion-weighted MRI (WB-DWI\/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: A pilot study. BMC Med Imaging. 2021;21:18. https:\/\/doi.org\/10.1186\/s12880-021-00550-2.","journal-title":"BMC Med Imaging"},{"key":"8011_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmri.24586","volume":"41","author":"I Joo","year":"2015","unstructured":"Joo I, Lee JM, Kim JH, Shin C, Han JK, Choi BI. Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer. Magn Reson Imaging. 2015;41:814\u201321. https:\/\/doi.org\/10.1002\/jmri.24586.","journal-title":"Magn Reson Imaging"},{"key":"8011_CR14","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1007\/s00261-022-03623-0","volume":"47","author":"J Li","year":"2022","unstructured":"Li J, Yan L, Zhang H, Wang Y, Xu S, Li H, et al. Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer. Abdom Radiol. 2022;47:3394\u2013405. https:\/\/doi.org\/10.1007\/s00261-022-03623-0.","journal-title":"Abdom Radiol"},{"key":"8011_CR15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/MNM.0000000000001481","volume":"42","author":"F Dondi","year":"2021","unstructured":"Dondi F, Albano D, Giubbini R, Bertagna F. 18F-FDG PET and PET\/CT for the evaluation of gastric signet ring cell carcinoma: A systematic review. Nucl Med Commun. 2021;42:1293\u2013300. https:\/\/doi.org\/10.1097\/MNM.0000000000001481.","journal-title":"Nucl Med Commun"},{"key":"8011_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3892\/etm.2020.9595","volume":"21","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zheng B, Chen W, Xiong H, Jiang C. Accuracy of18 F\u2013FDG PET\/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta\u2013analysis. Exp Ther Med. 2020;21:164. https:\/\/doi.org\/10.3892\/etm.2020.9595.","journal-title":"Exp Ther Med"},{"key":"8011_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11307-018-1273-0","volume":"21","author":"JD Peterson","year":"2019","unstructured":"Peterson JD. Paradigms in Fluorescence Molecular Imaging: Maximizing Measurement of Biological Changes in Disease, Therapeutic Efficacy, and Toxicology\/Safety. Mol Imaging Biol. 2019;21:599\u2013611. https:\/\/doi.org\/10.1007\/s11307-018-1273-0.","journal-title":"Mol Imaging Biol"},{"key":"8011_CR18","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.3390\/curroncol29090513","volume":"29","author":"D Ma","year":"2022","unstructured":"Ma D, Zhang Y, Shao X, Wu C, Wu J. PET\/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer. Curr Oncol. 2022;29:6523\u201339. https:\/\/doi.org\/10.3390\/curroncol29090513.","journal-title":"Curr Oncol"},{"key":"8011_CR19","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1097\/MD.0000000000001037","volume":"94","author":"B-I Song","year":"2015","unstructured":"Song B-I, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET\/CT Improves the Prediction of Prognosis in Gastric Cancer. Med (Baltim). 2015;94:e1037. https:\/\/doi.org\/10.1097\/MD.0000000000001037.","journal-title":"Med (Baltim)"},{"key":"8011_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cpet.2017.05.004","volume":"12","author":"C Marcus","year":"2017","unstructured":"Marcus C, Subramaniam RM. PET\/Computed Tomography and Precision Medicine: Gastric Cancer. PET Clin. 2017;12:437\u201347. https:\/\/doi.org\/10.1016\/j.cpet.2017.05.004.","journal-title":"PET Clin"},{"key":"8011_CR21","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.3390\/molecules25204621","volume":"25","author":"K Mandleywala","year":"2020","unstructured":"Mandleywala K, Shmuel S, Pereira PMR, Lewis JS. Antibody-Targeted Imaging of Gastric Cancer. Molecules. 2020;25:4621. https:\/\/doi.org\/10.3390\/molecules25204621.","journal-title":"Molecules"},{"key":"8011_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.semnuclmed.2022.01.004","volume":"52","author":"P Ritt","year":"2022","unstructured":"Ritt P. Recent Developments in SPECT\/CT. Semin Nucl Med. 2022;52:276\u201385. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.01.004.","journal-title":"Semin Nucl Med"},{"key":"8011_CR23","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/jcm12154882","volume":"12","author":"J McGale","year":"2023","unstructured":"McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, et al. PET\/CT and SPECT\/CT Imaging of HER2-Positive Breast Cancer. J Clin Med. 2023;12:4882. https:\/\/doi.org\/10.3390\/jcm12154882.","journal-title":"J Clin Med"},{"key":"8011_CR24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2967\/jnumed.124.267964","volume":"65","author":"O Tuncer","year":"2024","unstructured":"Tuncer O, Steinberger D, Steiner J, Hinojos M, Rhee SY, Humphrey B, et al. Quantitative SPECT\/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients. J Nucl Med. 2024;65:1584\u201390. https:\/\/doi.org\/10.2967\/jnumed.124.267964.","journal-title":"J Nucl Med"},{"key":"8011_CR25","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1097\/RLU.0000000000005554","volume":"50","author":"N Raeisi","year":"2025","unstructured":"Raeisi N, Tanha AS, Aryana K, Soltani E, Barashki S. Utilizing 99m Tc-FAPI-46 SPECT\/CT in detection of peritoneal carcinomatosis in gastric poorly differentiated adenocarcinoma: a case report. Clin Nucl Med. 2025;50:e122\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000005554.","journal-title":"Clin Nucl Med"},{"key":"8011_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/RLU.0b013e3182a43089","volume":"38","author":"H Zhao","year":"2013","unstructured":"Zhao H, Han J, Lv F, Zhang C. 99mTc-MDP uptake in implantation metastasis of gastric cancer: the additional value of SPECT\/CT. Clin Nucl Med. 2013;38:838\u201340. https:\/\/doi.org\/10.1097\/RLU.0b013e3182a43089.","journal-title":"Clin Nucl Med"},{"key":"8011_CR27","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1007\/s00259-022-05894-7","volume":"49","author":"P Cen","year":"2022","unstructured":"Cen P, Zhou Y, Cui C, Wei Y, Cheng Z, Wu S, et al. Optical molecular imaging and theranostics in neurological diseases based on aggregation-induced emission luminogens. Eur J Nucl Med Mol Imaging. 2022;49:4529\u201350. https:\/\/doi.org\/10.1007\/s00259-022-05894-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR28","doi-asserted-by":"publisher","first-page":"1250594","DOI":"10.3389\/fbioe.2023.1250594","volume":"11","author":"J Wei","year":"2023","unstructured":"Wei J, Liu C, Liang W, Yang X, Han S. Advances in optical molecular imaging for neural visualization. Front Bioeng Biotechnol. 2023;11:1250594. https:\/\/doi.org\/10.3389\/fbioe.2023.1250594.","journal-title":"Front Bioeng Biotechnol"},{"key":"8011_CR29","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00259-022-05730-y","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, He K, Chi C, Hu Z, Tian J. Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China. Eur J Nucl Med Mol Imaging. 2022;49:2531\u201343. https:\/\/doi.org\/10.1007\/s00259-022-05730-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR30","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/cancers17081352","volume":"17","author":"BE Zweedijk","year":"2025","unstructured":"Zweedijk BE, Dalmeijer SWR, van Manen L, Galema HA, Lauwerends LJ, Abbasi H, et al. Molecular-Targeted Fluorescence Lymph Node Imaging Could Play a Clinical Role in the Surgical Setting: A Systematic Review. Cancers (Basel). 2025;17:1352. https:\/\/doi.org\/10.3390\/cancers17081352.","journal-title":"Cancers (Basel)"},{"key":"8011_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.molmed.2020.02.003","volume":"26","author":"Z Hu","year":"2020","unstructured":"Hu Z, Chen W-H, Tian J, Cheng Z. NIRF Nanoprobes for Cancer Molecular Imaging: Approaching Clinic. Trends Mol Med. 2020;26:469\u201382. https:\/\/doi.org\/10.1016\/j.molmed.2020.02.003.","journal-title":"Trends Mol Med"},{"key":"8011_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00345-019-02870-z","volume":"38","author":"GE Cacciamani","year":"2020","unstructured":"Cacciamani GE, Shakir A, Tafuri A, Gill K, Han J, Ahmadi N, et al. Best practices in near-infrared fluorescence imaging with indocyanine green (NIRF\/ICG)-guided robotic urologic surgery: a systematic review-based expert consensus. World J Urol. 2020;38:883\u201396. https:\/\/doi.org\/10.1007\/s00345-019-02870-z.","journal-title":"World J Urol"},{"key":"8011_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1021\/acs.bioconjchem.1c00520","volume":"33","author":"Z Li","year":"2022","unstructured":"Li Z, Zhang C, Zhang X, Sui J, Jin L, Lin L, et al. NIR-II Functional Materials for Photoacoustic Theranostics. Bioconjug Chem. 2022;33:67\u201386. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00520.","journal-title":"Bioconjug Chem"},{"key":"8011_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41571-024-00892-0","volume":"21","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Du Y, Shi X, Wang K, Qu Q, Liang Q, et al. NIR-II light in clinical oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:449\u201367. https:\/\/doi.org\/10.1038\/s41571-024-00892-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"8011_CR35","doi-asserted-by":"publisher","first-page":"e2021446118","DOI":"10.1073\/pnas.2021446118","volume":"118","author":"Z Ma","year":"2021","unstructured":"Ma Z, Wang F, Wang W, Zhong Y, Dai H. Deep learning for in vivo near-infrared imaging. Proc Natl Acad Sci USA. 2021;118:e2021446118. https:\/\/doi.org\/10.1073\/pnas.2021446118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8011_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/ph15040432","volume":"15","author":"M Kubeil","year":"2022","unstructured":"Kubeil M, Mart\u00ednez IIS, Bachmann M, Kopka K, Tuck KL, Stephan H. Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives. Pharmaceuticals (Basel). 2022;15:432. https:\/\/doi.org\/10.3390\/ph15040432.","journal-title":"Pharmaceuticals (Basel)"},{"key":"8011_CR37","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1039\/d5ra03102h","volume":"15","author":"NW Nkune","year":"2025","unstructured":"Nkune NW, Moloudi K, George BP, Abrahamse H. An update on recent advances in fluorescent materials for fluorescence molecular imaging: a review. RSC Adv. 2025;15:22267\u201384. https:\/\/doi.org\/10.1039\/d5ra03102h.","journal-title":"RSC Adv"},{"key":"8011_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1109\/RBME.2020.2995124","volume":"14","author":"N Alsawaftah","year":"2021","unstructured":"Alsawaftah N, Farooq A, Dhou S, Majdalawieh AF. Bioluminescence Imaging Applications in Cancer: A Comprehensive Review. IEEE Rev Biomed Eng. 2021;14:307\u201326. https:\/\/doi.org\/10.1109\/RBME.2020.2995124.","journal-title":"IEEE Rev Biomed Eng"},{"key":"8011_CR39","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/cbf.70020","volume":"42","author":"B Sangeetha","year":"2024","unstructured":"Sangeetha B, Leroy KI, Udaya Kumar B. Harnessing Bioluminescence: A Comprehensive Review of In Vivo Imaging for Disease Monitoring and Therapeutic Intervention. Cell Biochem Funct. 2024;42:e70020. https:\/\/doi.org\/10.1002\/cbf.70020.","journal-title":"Cell Biochem Funct"},{"key":"8011_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1513\/pats.200507-067DS","volume":"2","author":"RT Sadikot","year":"2005","unstructured":"Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc. 2005;2:537\u201340. https:\/\/doi.org\/10.1513\/pats.200507-067DS.","journal-title":"Proc Am Thorac Soc"},{"key":"8011_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cbpa.2021.02.005","volume":"63","author":"G Zambito","year":"2021","unstructured":"Zambito G, Chawda C, Mezzanotte L. Emerging tools for bioluminescence imaging. Curr Opin Chem Biol. 2021;63:86\u201394. https:\/\/doi.org\/10.1016\/j.cbpa.2021.02.005.","journal-title":"Curr Opin Chem Biol"},{"key":"8011_CR42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1039\/d1ob01940f","volume":"20","author":"X Yang","year":"2022","unstructured":"Yang X, Qin X, Ji H, Du L, Li M. Constructing firefly luciferin bioluminescence probes for in vivo imaging. Org Biomol Chem. 2022;20:1360\u201372. https:\/\/doi.org\/10.1039\/d1ob01940f.","journal-title":"Org Biomol Chem"},{"key":"8011_CR43","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.3390\/ijms24043151","volume":"24","author":"N Vladimirov","year":"2023","unstructured":"Vladimirov N, Perlman O. Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. Int J Mol Sci. 2023;24:3151. https:\/\/doi.org\/10.3390\/ijms24043151.","journal-title":"Int J Mol Sci"},{"key":"8011_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11604-025-01732-6","volume":"43","author":"K Yokoyama","year":"2025","unstructured":"Yokoyama K, Matsuki M, Isozaki T, Ito K, Imokawa T, Ozawa A, et al. Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine. Jpn J Radiol. 2025;43:903\u201326. https:\/\/doi.org\/10.1007\/s11604-025-01732-6.","journal-title":"Jpn J Radiol"},{"key":"8011_CR45","doi-asserted-by":"publisher","first-page":"e2407262","DOI":"10.1002\/adma.202407262","volume":"36","author":"Y Ning","year":"2024","unstructured":"Ning Y, Zhou IY, Caravan P. Quantitative in Vivo Molecular MRI. Adv Mater. 2024;36:e2407262. https:\/\/doi.org\/10.1002\/adma.202407262.","journal-title":"Adv Mater"},{"key":"8011_CR46","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","volume":"22","author":"F Grillo","year":"2016","unstructured":"Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric\/gastroesophageal cancers: From benchside to practice. World J Gastroenterol. 2016;22:5879\u201387. https:\/\/doi.org\/10.3748\/wjg.v22.i26.5879.","journal-title":"World J Gastroenterol"},{"key":"8011_CR47","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22:4619\u201325. https:\/\/doi.org\/10.3748\/wjg.v22.i19.4619.","journal-title":"World J Gastroenterol"},{"key":"8011_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10020-023-00736-0","volume":"29","author":"L Guo","year":"2023","unstructured":"Guo L, Shao W, Zhou C, Yang H, Yang L, Cai Q, et al. Neratinib for HER2-positive breast cancer with an overlooked option. Mol Med. 2023;29:134. https:\/\/doi.org\/10.1186\/s10020-023-00736-0.","journal-title":"Mol Med"},{"key":"8011_CR49","unstructured":"HER2\/PI3K\/AKT pathway. in HER2-positive breast cancer: a review - PubMed [Internet]. [cited 2025 July 31]. https:\/\/pubmed.ncbi.nlm.nih.gov\/38875362\/. Accessed 31 July 2025."},{"key":"8011_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127\u201337. https:\/\/doi.org\/10.1038\/35052073.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8011_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20:209\u201315. https:\/\/doi.org\/10.1038\/s41577-019-0264-y.","journal-title":"Nat Rev Immunol"},{"key":"8011_CR52","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331:1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"key":"8011_CR53","doi-asserted-by":"publisher","first-page":"925","DOI":"10.5114\/ada.2021.112274","volume":"38","author":"M Adamczyk","year":"2021","unstructured":"Adamczyk M, Krasowska D. PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: a review. Postepy Dermatol Alergol. 2021;38:925\u201330. https:\/\/doi.org\/10.5114\/ada.2021.112274.","journal-title":"Postepy Dermatol Alergol"},{"key":"8011_CR54","doi-asserted-by":"publisher","first-page":"1226038","DOI":"10.3389\/fimmu.2023.1226038","volume":"14","author":"Y-C Zhang","year":"2023","unstructured":"Zhang Y-C, Zhang Y-T, Wang Y, Zhao Y, He L-J. What role does PDL1 play in EMT changes in tumors and fibrosis? Front Immunol. 2023;14:1226038. https:\/\/doi.org\/10.3389\/fimmu.2023.1226038.","journal-title":"Front Immunol"},{"key":"8011_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14:10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5.","journal-title":"J Hematol Oncol"},{"key":"8011_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38. https:\/\/doi.org\/10.1186\/s40364-022-00385-1.","journal-title":"Biomark Res"},{"key":"8011_CR57","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","volume":"39","author":"JH Baek","year":"2019","unstructured":"Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, et al. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. Anticancer Res. 2019;39:6973\u20139. https:\/\/doi.org\/10.21873\/anticanres.13919.","journal-title":"Anticancer Res"},{"key":"8011_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121:257\u201363. https:\/\/doi.org\/10.1038\/s41416-019-0508-4.","journal-title":"Br J Cancer"},{"key":"8011_CR59","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, T\u00fcreci \u00d6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49:870\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyz068.","journal-title":"Jpn J Clin Oncol"},{"key":"8011_CR60","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1007\/s00018-019-03238-7","volume":"76","author":"H Kage","year":"2019","unstructured":"Kage H, Flodby P, Zhou B, Borok Z. Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice. Cell Mol Life Sci. 2019;76:4663\u201372. https:\/\/doi.org\/10.1007\/s00018-019-03238-7.","journal-title":"Cell Mol Life Sci"},{"key":"8011_CR61","doi-asserted-by":"publisher","first-page":"154699","DOI":"10.1016\/j.prp.2023.154699","volume":"248","author":"D Tao","year":"2023","unstructured":"Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract. 2023;248:154699. https:\/\/doi.org\/10.1016\/j.prp.2023.154699.","journal-title":"Pathol Res Pract"},{"key":"8011_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","volume":"403","author":"K Takasawa","year":"2017","unstructured":"Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, et al. Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett. 2017;403:66\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.033.","journal-title":"Cancer Lett"},{"key":"8011_CR63","doi-asserted-by":"publisher","first-page":"e74757","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T, Chen X, Hori K, Tomita T, et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS ONE. 2013;8:e74757. https:\/\/doi.org\/10.1371\/journal.pone.0074757.","journal-title":"PLoS ONE"},{"key":"8011_CR64","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","volume":"155","author":"SJ Hagen","year":"2018","unstructured":"Hagen SJ, Ang L-H, Zheng Y, Karahan SN, Wu J, Wang YE, et al. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach. Gastroenterology. 2018;155:1852\u201367. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.041.","journal-title":"Gastroenterology"},{"key":"8011_CR65","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1172\/JCI90429","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou B, Flodby P, Luo J, Castillo DR, Liu Y, Yu F-X, et al. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Invest. 2018;128:970\u201384. https:\/\/doi.org\/10.1172\/JCI90429.","journal-title":"J Clin Invest"},{"key":"8011_CR66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1172\/JCI99799","volume":"128","author":"DN Kotton","year":"2018","unstructured":"Kotton DN. Claudin-18: unexpected regulator of lung alveolar epithelial cell proliferation. J Clin Invest. 2018;128:903\u20135. https:\/\/doi.org\/10.1172\/JCI99799.","journal-title":"J Clin Invest"},{"key":"8011_CR67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL. Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019;16:282\u201395. https:\/\/doi.org\/10.1038\/s41575-019-0115-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8011_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12253-017-0359-3","volume":"25","author":"L-M Gao","year":"2019","unstructured":"Gao L-M, Wang F, Zheng Y, Fu Z-Z, Zheng L, Chen L-L. Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer. Pathol Oncol Res. 2019;25:369\u201376. https:\/\/doi.org\/10.1007\/s12253-017-0359-3.","journal-title":"Pathol Oncol Res"},{"key":"8011_CR69","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1186\/s12885-018-5035-9","volume":"18","author":"J Liu","year":"2018","unstructured":"Liu J, Huang C, Peng C, Xu F, Li Y, Yutaka Y, et al. Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt\/ \u03b2-catenin pathway. BMC Cancer. 2018;18:1099. https:\/\/doi.org\/10.1186\/s12885-018-5035-9.","journal-title":"BMC Cancer"},{"key":"8011_CR70","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3727\/096504016X14768383625385","volume":"25","author":"X Wen","year":"2017","unstructured":"Wen X, He X, Jiao F, Wang C, Sun Y, Ren X, et al. Fibroblast Activation Protein-\u03b1-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade. Oncol Res. 2017;25:629\u201340. https:\/\/doi.org\/10.3727\/096504016X14768383625385.","journal-title":"Oncol Res"},{"key":"8011_CR71","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/cells10051201","volume":"10","author":"HR Ferguson","year":"2021","unstructured":"Ferguson HR, Smith MP, Francavilla C. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cells. 2021;10:1201. https:\/\/doi.org\/10.3390\/cells10051201.","journal-title":"Cells"},{"key":"8011_CR72","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/MCB.20.3.979-989.2000","volume":"20","author":"SH Ong","year":"2000","unstructured":"Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J, et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol. 2000;20:979\u201389. https:\/\/doi.org\/10.1128\/MCB.20.3.979-989.2000.","journal-title":"Mol Cell Biol"},{"key":"8011_CR73","doi-asserted-by":"publisher","first-page":"e0195513","DOI":"10.1371\/journal.pone.0195513","volume":"13","author":"Y Arkun","year":"2018","unstructured":"Arkun Y, Yasemi M. Dynamics and control of the ERK signaling pathway: Sensitivity, bistability, and oscillations. PLoS ONE. 2018;13:e0195513. https:\/\/doi.org\/10.1371\/journal.pone.0195513.","journal-title":"PLoS ONE"},{"key":"8011_CR74","doi-asserted-by":"publisher","first-page":"188619","DOI":"10.1016\/j.bbcan.2021.188619","volume":"1876","author":"S Mandal","year":"2021","unstructured":"Mandal S, Bandyopadhyay S, Tyagi K, Roy A. Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis. Biochim Biophys Acta Rev Cancer. 2021;1876:188619. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188619.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8011_CR75","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fcell.2020.00079","volume":"8","author":"M Mossahebi-Mohammadi","year":"2020","unstructured":"Mossahebi-Mohammadi M, Quan M, Zhang J-S, Li X. FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency. Front Cell Dev Biol. 2020;8:79. https:\/\/doi.org\/10.3389\/fcell.2020.00079.","journal-title":"Front Cell Dev Biol"},{"key":"8011_CR76","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.3390\/cancers13225796","volume":"13","author":"J Szymczyk","year":"2021","unstructured":"Szymczyk J, Sluzalska KD, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF\/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers (Basel). 2021;13:5796. https:\/\/doi.org\/10.3390\/cancers13225796.","journal-title":"Cancers (Basel)"},{"key":"8011_CR77","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bo\u015fca AB, \u015eu\u015fman S, M\u0103rginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455\u201367.","journal-title":"Rom J Morphol Embryol"},{"key":"8011_CR78","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41401-021-00803-4","volume":"43","author":"H-J Wang","year":"2022","unstructured":"Wang H-J, Ran H-F, Yin Y, Xu X-G, Jiang B-X, Yu S-Q, et al. Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K\/AKT and VEGF-MEK1\/2\/ERK1\/2 signaling. Acta Pharmacol Sin. 2022;43:1670\u201385. https:\/\/doi.org\/10.1038\/s41401-021-00803-4.","journal-title":"Acta Pharmacol Sin"},{"key":"8011_CR79","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.4161\/cc.20535","volume":"11","author":"G-X Ruan","year":"2012","unstructured":"Ruan G-X, Kazlauskas A. VEGF-A engages at least three tyrosine kinases to activate PI3K\/Akt. Cell Cycle. 2012;11:2047\u20138. https:\/\/doi.org\/10.4161\/cc.20535.","journal-title":"Cell Cycle"},{"key":"8011_CR80","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jcb.30344","volume":"123","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Nawaz MI. Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem. 2022;123:1938\u201365. https:\/\/doi.org\/10.1002\/jcb.30344.","journal-title":"J Cell Biochem"},{"key":"8011_CR81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular Mechanisms and Future Implications of VEGF\/VEGFR in Cancer Therapy. Clin Cancer Res. 2023;29:30\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1366.","journal-title":"Clin Cancer Res"},{"key":"8011_CR82","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","volume":"111","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol. 2022;111:1269\u201386. https:\/\/doi.org\/10.1002\/JLB.5RU0222-082R.","journal-title":"J Leukoc Biol"},{"key":"8011_CR83","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.tranon.2023.101665","volume":"32","author":"S Qiao","year":"2023","unstructured":"Qiao S, Hou Y, Rong Q, Han B, Liu P. Tregs are involved in VEGFA\/ VASH1-related angiogenesis pathway in ovarian cancer. Transl Oncol. 2023;32:101665. https:\/\/doi.org\/10.1016\/j.tranon.2023.101665.","journal-title":"Transl Oncol"},{"key":"8011_CR84","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","volume":"8","author":"T Liu","year":"2013","unstructured":"Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS ONE. 2013;8:e75864. https:\/\/doi.org\/10.1371\/journal.pone.0075864.","journal-title":"PLoS ONE"},{"key":"8011_CR85","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.neo.2021.07.002","volume":"23","author":"E Guerra","year":"2021","unstructured":"Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Vacca G, et al. Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer. Neoplasia. 2021;23:898\u2013911. https:\/\/doi.org\/10.1016\/j.neo.2021.07.002.","journal-title":"Neoplasia"},{"key":"8011_CR86","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cancers12113328","volume":"12","author":"S Len\u00e1rt","year":"2020","unstructured":"Len\u00e1rt S, Len\u00e1rt P, \u0160marda J, Rem\u0161\u00edk J, Sou\u010dek K, Bene\u0161 P. Trop2: Jack of All Trades, Master of None. Cancers (Basel). 2020;12:3328. https:\/\/doi.org\/10.3390\/cancers12113328.","journal-title":"Cancers (Basel)"},{"key":"8011_CR87","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.120.246595","volume":"62","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab\u2019)2 Fragments of Obinutuzumab in Lymphoma. J Nucl Med. 2021;62:372\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.246595.","journal-title":"J Nucl Med"},{"key":"8011_CR88","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1021\/acs.molpharmaceut.8b00673","volume":"15","author":"X Guo","year":"2018","unstructured":"Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, et al. Noninvasive detection of HER2 expression in gastric cancer by64 cu-NOTA-trastuzumab in PDX mouse model and in patients. Mol Pharm. 2018;15:5174\u201382. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00673.","journal-title":"Mol Pharm"},{"key":"8011_CR89","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10120-019-01035-6","volume":"23","author":"X Guo","year":"2020","unstructured":"Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X, et al. Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: From patient-derived xenograft models to gastric cancer patients. Gastric Cancer. 2020;23:614\u201326. https:\/\/doi.org\/10.1007\/s10120-019-01035-6.","journal-title":"Gastric Cancer"},{"key":"8011_CR90","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1039\/c8ra10271f","volume":"9","author":"Y Pan","year":"2019","unstructured":"Pan Y, Yang Z, Xu Y, Bai Z, Pan D, Yang R, et al. Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe. RSC Adv. 2019;9:10990\u20138. https:\/\/doi.org\/10.1039\/c8ra10271f.","journal-title":"RSC Adv"},{"key":"8011_CR91","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00259-020-04898-5","volume":"48","author":"N Zhou","year":"2021","unstructured":"Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C, et al. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2021;48:161\u201375. https:\/\/doi.org\/10.1007\/s00259-020-04898-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR92","doi-asserted-by":"publisher","first-page":"803005","DOI":"10.3389\/fmed.2022.803005","volume":"9","author":"J Han","year":"2022","unstructured":"Han J, Chen Y, Zhao Y, Zhao X, Zhang J, Wang J, et al. Pre-clinical study of the [18F]AlF-labeled HER2 affibody for non-invasive HER2 detection in gastric cancer. Front Med (Lausanne). 2022;9:803005. https:\/\/doi.org\/10.3389\/fmed.2022.803005.","journal-title":"Front Med (Lausanne)"},{"key":"8011_CR93","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s00259-023-06232-1","volume":"50","author":"J Liu","year":"2023","unstructured":"Liu J, Guo X, Wen L, Wang L, Liu F, Song G, et al. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. Eur J Nucl Med Mol Imaging. 2023;50:2775\u201386. https:\/\/doi.org\/10.1007\/s00259-023-06232-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR94","doi-asserted-by":"publisher","DOI":"10.1021\/acs.inorgchem.5c01513","author":"J Pineau","year":"2025","unstructured":"Pineau J, Ollier C, Mothes C, Belderbos S, Le Bris N, Tripier R. Advanced 64Cu\/67Cu-based theranostics: Application of the copper chelator TE1PA to a murine model of HER2-positive gastric cancer. Inorg Chem. 2025. https:\/\/doi.org\/10.1021\/acs.inorgchem.5c01513.","journal-title":"Inorg Chem"},{"key":"8011_CR95","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res"},{"key":"8011_CR96","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"8011_CR97","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"8011_CR98","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1021\/acs.molpharmaceut.4c00155","volume":"21","author":"J Wu","year":"2024","unstructured":"Wu J, Chen J, Zhao Y, Yuan M, Chen X, He X, et al. Molecular SPECT\/CT profiling of Claudin18.2 expression in vivo: Implication for patients with gastric cancer. Mol Pharm. 2024;21:3447\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00155.","journal-title":"Mol Pharm"},{"key":"8011_CR99","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1021\/acs.molpharmaceut.1c00947","volume":"19","author":"C Zhao","year":"2022","unstructured":"Zhao C, Rong Z, Ding J, Wang L, Wang B, Ding L, et al. Targeting claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery. Mol Pharm. 2022;19:3530\u201341. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00947.","journal-title":"Mol Pharm"},{"key":"8011_CR100","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jpha.2023.02.011","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y, Hou X, Li D, Ding J, Liu J, Wang Z, et al. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. J Pharm Anal. 2023;13:367\u201375. https:\/\/doi.org\/10.1016\/j.jpha.2023.02.011.","journal-title":"J Pharm Anal"},{"key":"8011_CR101","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","volume":"51","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Li L, Tao J, Liu J, Li H, Qian X, et al. [177Lu]lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. Eur J Nucl Med Mol Imaging. 2024;51:1221\u201332. https:\/\/doi.org\/10.1007\/s00259-023-06561-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR102","doi-asserted-by":"publisher","first-page":"116134","DOI":"10.1016\/j.ejmech.2024.116134","volume":"266","author":"D Li","year":"2024","unstructured":"Li D, Ding L, Chen Y, Wang Z, Zeng Z, Ma X, et al. Exploration of radionuclide labeling of a novel scFv-fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment. Eur J Med Chem. 2024;266:116134. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116134.","journal-title":"Eur J Med Chem"},{"key":"8011_CR103","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/IJN.S501689","volume":"20","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, et al. Utility of 131I-HLX58-der for the precision treatment: Evaluation of a preclinical radio-antibody-drug-conjugate approach in mouse models. Int J Nanomed. 2025;20:723\u201339. https:\/\/doi.org\/10.2147\/IJN.S501689.","journal-title":"Int J Nanomed"},{"key":"8011_CR104","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.omto.2022.11.003","volume":"27","author":"W Wei","year":"2022","unstructured":"Wei W, Zhang D, Zhang Y, Li L, Jin Y, An S, et al. Development and comparison of 68Ga\/18F\/64Cu-labeled nanobody tracers probing Claudin18.2. Mol Therapy - Oncolytics. 2022;27:305\u201314. https:\/\/doi.org\/10.1016\/j.omto.2022.11.003.","journal-title":"Mol Therapy - Oncolytics"},{"key":"8011_CR105","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1021\/acsptsci.4c00280","volume":"7","author":"Z Bai","year":"2024","unstructured":"Bai Z, Xie X, Li C, Wang Y, Wang Y, Li H, et al. Claudin18.2-targeted SPECT\/CT imaging for gastric cancer: Preclinical evaluation and clinical translation of the99m tc-labeled nanobody (PHG102) radiotracer. ACS Pharmacol Transl Sci. 2024;7:2465\u201375. https:\/\/doi.org\/10.1021\/acsptsci.4c00280.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"8011_CR106","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsptsci.3c00165","volume":"6","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhao C, Ding J, Chen Y, Liu J, Hou X, et al. Screening, construction, and preliminary evaluation of CLDN18.2-specific peptides for noninvasive molecular imaging. ACS Pharmacol Transl Sci. 2023;6:1829\u201340. https:\/\/doi.org\/10.1021\/acsptsci.3c00165.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"8011_CR107","doi-asserted-by":"publisher","first-page":"e2413913","DOI":"10.1002\/advs.202413913","volume":"12","author":"X Wang","year":"2025","unstructured":"Wang X, Hui H, Han J, Guo T, Wang Y, Meng L, et al. A CLDN18.2-targeted nanoplatform manipulates magnetic hyperthermia spatiotemporally for synergistic immunotherapy in gastric cancer. Adv Sci (Weinh). 2025;12:e2413913. https:\/\/doi.org\/10.1002\/advs.202413913.","journal-title":"Adv Sci (Weinh)"},{"key":"8011_CR108","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00259-023-06234-z","volume":"50","author":"S Wang","year":"2023","unstructured":"Wang S, Qi C, Ding J, Li D, Zhang M, Ji C, et al. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging. 2023;50:2802\u201317. https:\/\/doi.org\/10.1007\/s00259-023-06234-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR109","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2967\/jnumed.123.267110","volume":"65","author":"C Qi","year":"2024","unstructured":"Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, et al. 68 ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal cancer patients. J Nucl Med. 2024;65:856\u201363. https:\/\/doi.org\/10.2967\/jnumed.123.267110.","journal-title":"J Nucl Med"},{"key":"8011_CR110","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1007\/s00259-024-06808-5","volume":"51","author":"R Wang","year":"2024","unstructured":"Wang R, Bai Z, Zhong W, Li C, Wang J, Xiang J, et al. Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer. Eur J Nucl Med Mol Imaging. 2024;51:3731\u201343. https:\/\/doi.org\/10.1007\/s00259-024-06808-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR111","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","volume":"75","author":"S Heskamp","year":"2015","unstructured":"Heskamp S, Hobo W, Molkenboer-Kuenen JDM, Olive D, Oyen WJG, Dolstra H, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti\u2013PD-L1 antibodies. Cancer Res. 2015;75:2928\u201336. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3477.","journal-title":"Cancer Res"},{"key":"8011_CR112","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.18632\/oncotarget.7143","volume":"7","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7:10215\u201327. https:\/\/doi.org\/10.18632\/oncotarget.7143.","journal-title":"Oncotarget"},{"key":"8011_CR113","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, Van Der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0255-8.","journal-title":"Nat Med"},{"key":"8011_CR114","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","volume":"27","author":"Y-N Wang","year":"2020","unstructured":"Wang Y-N, Lee H-H, Hsu JL, Yu D, Hung M-C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27:77. https:\/\/doi.org\/10.1186\/s12929-020-00670-x.","journal-title":"J Biomed Sci"},{"key":"8011_CR115","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acs.jproteome.0c00521","volume":"20","author":"J Benicky","year":"2021","unstructured":"Benicky J, Sanda M, Brnakova Kennedy Z, Grant OC, Woods RJ, Zwart A, et al. PD-L1 glycosylation and its impact on binding to clinical antibodies. J Proteome Res. 2021;20:485\u201397. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00521.","journal-title":"J Proteome Res"},{"key":"8011_CR116","doi-asserted-by":"publisher","first-page":"153601211985218","DOI":"10.1177\/1536012119852189","volume":"18","author":"WG Lesniak","year":"2019","unstructured":"Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, et al. Development of [18 F]FPy-WL12 as a PD-L1 specific PET imaging peptide. Mol Imaging. 2019;18:1536012119852189. https:\/\/doi.org\/10.1177\/1536012119852189.","journal-title":"Mol Imaging"},{"key":"8011_CR117","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1021\/acs.molpharmaceut.8b00399","volume":"15","author":"RA De Silva","year":"2018","unstructured":"De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Venkateswara Rao K, et al. Peptide-Based68 ga-PET radiotracer for imaging PD-L1 expression in cancer. Mol Pharm. 2018;15:3946\u201352. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00399.","journal-title":"Mol Pharm"},{"key":"8011_CR118","doi-asserted-by":"publisher","unstructured":"Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B et al. Corrigendum to rapid PD-L1 detection in tumors with PET using a highly specific peptide [biochemical and biophysical research communications 483\/1 (2017) 258\u2013263]. Biochemical and Biophys Res Commun. 2017;491:1125. https:\/\/doi.org\/10.1016\/j.bbrc.2017.08.001","DOI":"10.1016\/j.bbrc.2017.08.001"},{"key":"8011_CR119","doi-asserted-by":"publisher","first-page":"e2107982118","DOI":"10.1073\/pnas.2107982118","volume":"118","author":"D Kumar","year":"2021","unstructured":"Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci USA. 2021;118:e2107982118. https:\/\/doi.org\/10.1073\/pnas.2107982118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8011_CR120","doi-asserted-by":"publisher","first-page":"105682","DOI":"10.1016\/j.bioorg.2022.105682","volume":"122","author":"P Sun","year":"2022","unstructured":"Sun P, Han Y, Hu K, Huang S, Wang M, Zhou K, et al. Synthesis and biological evaluation of al[18F]-NOTA-IPB-PDL1P as a molecular probe for PET imaging of PD-L1 positive tumors. Bioorg Chem. 2022;122:105682. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105682.","journal-title":"Bioorg Chem"},{"key":"8011_CR121","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00259-023-06527-3","volume":"51","author":"DJ Donnelly","year":"2024","unstructured":"Donnelly DJ, Kim J, Tran T, Scola PM, Tenney D, Pena A, et al. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024;51:978\u201390. https:\/\/doi.org\/10.1007\/s00259-023-06527-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR122","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2967\/jnumed.123.267186","volume":"65","author":"SL Cytryn","year":"2024","unstructured":"Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, et al. 18 F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer. J Nucl Med. 2024;65:722\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.267186.","journal-title":"J Nucl Med"},{"key":"8011_CR123","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1007\/s00259-022-05799-5","volume":"49","author":"R Lin","year":"2022","unstructured":"Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [68Ga]ga-DOTA-FAPI-04 PET\/CT in the evaluation of gastric cancer: Comparison with [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2022;49:2960\u201371. https:\/\/doi.org\/10.1007\/s00259-022-05799-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR124","doi-asserted-by":"publisher","first-page":"925100","DOI":"10.3389\/fonc.2022.925100","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wang W, Xu T, Ding H, Li Y, Liu H, et al. Comparison of diagnostic efficacy of [68Ga]ga-FAPI-04 and [18F]FDG PET\/CT for staging and restaging of gastric cancer. Front Oncol. 2022;12:925100. https:\/\/doi.org\/10.3389\/fonc.2022.925100.","journal-title":"Front Oncol"},{"key":"8011_CR125","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.7150\/thno.88335","volume":"13","author":"D Ruan","year":"2023","unstructured":"Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, et al. Evaluation of FAPI PET imaging in gastric cancer: A systematic review and meta-analysis. Theranostics. 2023;13:4694\u2013710. https:\/\/doi.org\/10.7150\/thno.88335.","journal-title":"Theranostics"},{"key":"8011_CR126","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.258467","volume":"63","author":"C Qin","year":"2022","unstructured":"Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68 ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: Comparison with18 F-FDG PET\/CT. J Nucl Med. 2022;63:81\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.258467.","journal-title":"J Nucl Med"},{"key":"8011_CR127","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Meng T, Xu W, Lin Q, Wu H, et al. PET imaging of fibroblast activation protein in various types of cancer Using68 ga-FAP-2286: Comparison with18 F-FDG and68 ga-FAPI-46 in a single-center, prospective study. J Nucl Med. 2023;64:386\u201394. https:\/\/doi.org\/10.2967\/jnumed.122.264544.","journal-title":"J Nucl Med"},{"key":"8011_CR128","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.123.266329","volume":"65","author":"W Xu","year":"2024","unstructured":"Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, et al. Fibroblast activation protein\u2013targeted PET\/CT with18 F-fibroblast activation protein inhibitor-74 for evaluation of gastrointestinal cancer: Comparison with18 F-FDG PET\/CT. J Nucl Med. 2024;65:40\u201351. https:\/\/doi.org\/10.2967\/jnumed.123.266329.","journal-title":"J Nucl Med"},{"key":"8011_CR129","doi-asserted-by":"publisher","first-page":"44","DOI":"10.62347\/GTZZ9726","volume":"15","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Li J, Chen P, Li Z, Yu Y. Evaluation of 18F-FAPI-42-RGD as a novel dual-targeting PET tracer in gastric cancer xenograft models. Am J Nucl Med Mol Imaging. 2025;15:44\u201354. https:\/\/doi.org\/10.62347\/GTZZ9726.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"8011_CR130","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","volume":"48","author":"X Zhang","year":"2021","unstructured":"Zhang X, Song W, Qin C, Liu F, Lan X. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021;48:2635\u201341. https:\/\/doi.org\/10.1007\/s00259-021-05194-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR131","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00259-023-06107-5","volume":"50","author":"L Chen","year":"2023","unstructured":"Chen L, Zhong X, Li L, Li X, Liu Y, Guo C, et al. [68Ga]ga-FAPI-04 PET\/CT on assessing crohn\u2019s disease intestinal lesions. Eur J Nucl Med Mol Imaging. 2023;50:1360\u201370. https:\/\/doi.org\/10.1007\/s00259-023-06107-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR132","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.clinre.2024.102466","volume":"48","author":"R Wu","year":"2024","unstructured":"Wu R, Yuan S, Wang Y, Nan Y, Chen Z, Yuan H, et al. Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2024;48:102466. https:\/\/doi.org\/10.1016\/j.clinre.2024.102466.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"8011_CR133","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1021\/acsmedchemlett.6b00498","volume":"8","author":"H Zhu","year":"2017","unstructured":"Zhu H, Zhao C, Liu F, Wang L, Feng J, Shou C, et al. 125 I\u2013F56 peptide as radioanalysis agent targeting VEGFR1 in mice xenografted with human gastric tumor. ACS Med Chem Lett. 2017;8:266\u20139. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00498.","journal-title":"ACS Med Chem Lett"},{"key":"8011_CR134","doi-asserted-by":"publisher","first-page":"127248","DOI":"10.1016\/j.bmcl.2020.127248","volume":"30","author":"Q Yu","year":"2020","unstructured":"Yu Q, Wang L, Ding J, Yang Z, Shou C, Zhao C, et al. Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice micro-SPECT imaging. Bioorg Med Chem Lett. 2020;30:127248. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127248.","journal-title":"Bioorg Med Chem Lett"},{"key":"8011_CR135","unstructured":"Zhu H, Zhao C, Liu F, Wang L, Feng J, Zhou Z, et al. Radiolabeling and evaluation of 64Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer."},{"key":"8011_CR136","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00259-025-07106-4","volume":"52","author":"W Huang","year":"2025","unstructured":"Huang W, Li L, Zhou Y, Yang Q, Mixdorf JC, Barnhart TE, et al. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody\u2013drug conjugate (trodelvy) for imaging in gastric cancer and triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2025;52:2369\u201383. https:\/\/doi.org\/10.1007\/s00259-025-07106-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8011_CR137","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c01223","author":"W Huang","year":"2025","unstructured":"Huang W, Chao F, Li R, Yang Y, Hsu JC, DeLuca MC, et al. Noninvasive evaluation of Trop2 expression Using64 cu-NOTA-trodelvy-F(ab\u2019)2 in gastric and pancreatic cancer. Mol Pharm. 2025. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01223. acs.molpharmaceut.5c01223.","journal-title":"Mol Pharm"},{"key":"8011_CR138","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","volume":"41","author":"L Gandullo-S\u00e1nchez","year":"2022","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A. HER3 in cancer: From the bench to the bedside. J Exp Clin Cancer Res. 2022;41:310. https:\/\/doi.org\/10.1186\/s13046-022-02515-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"8011_CR139","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11307-022-01763-9","volume":"25","author":"SA Esfahani","year":"2023","unstructured":"Esfahani SA, de Aguiar Ferreira C, Rotile NJ, Ataeinia B, Krishna S, Catalano OA, et al. HER3 PET imaging predicts response to pan receptor tyrosine kinase inhibition therapy in gastric cancer. Mol Imaging Biol. 2023;25:353\u201362. https:\/\/doi.org\/10.1007\/s11307-022-01763-9.","journal-title":"Mol Imaging Biol"},{"key":"8011_CR140","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cac2.12386","volume":"43","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J, et al. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination\/degradation of STAT1 in a GTP binding\u2010dependent modality. Cancer Commun. 2023;43:123\u201349. https:\/\/doi.org\/10.1002\/cac2.12386.","journal-title":"Cancer Commun"},{"key":"8011_CR141","doi-asserted-by":"publisher","first-page":"750376","DOI":"10.3389\/fonc.2021.750376","volume":"11","author":"J Yin","year":"2021","unstructured":"Yin J, Xin B, Zhang M, Hui X, Chai N, Hu H, et al. 68Ga-labeled GX1 dimer: A novel probe for PET\/cerenkov imaging targeting gastric cancer. Front Oncol. 2021;11:750376. https:\/\/doi.org\/10.3389\/fonc.2021.750376.","journal-title":"Front Oncol"},{"key":"8011_CR142","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.phrs.2023.106694","volume":"189","author":"Y Gu","year":"2023","unstructured":"Gu Y, Dong B, He X, Qiu Z, Zhang J, Zhang M, et al. The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: From bench to clinical trials. Pharmacol Res. 2023;189:106694. https:\/\/doi.org\/10.1016\/j.phrs.2023.106694.","journal-title":"Pharmacol Res"},{"key":"8011_CR143","doi-asserted-by":"publisher","first-page":"601538","DOI":"10.3389\/fonc.2020.601538","volume":"10","author":"K Li","year":"2020","unstructured":"Li K, Li P, Wang Y, Han S. Manganese-based targeted nanoparticles for postoperative gastric cancer monitoring via magnetic resonance imaging. Front Oncol. 2020;10:601538. https:\/\/doi.org\/10.3389\/fonc.2020.601538.","journal-title":"Front Oncol"},{"key":"8011_CR144","doi-asserted-by":"publisher","first-page":"e2203918","DOI":"10.1002\/advs.202203918","volume":"10","author":"Q Luo","year":"2023","unstructured":"Luo Q, Fan C, Ying W, Peng X, Hu Y, Luan Z, et al. In vivo anchoring bis-pyrene probe for molecular imaging of early gastric cancer by endoscopic techniques. Adv Sci (Weinh). 2023;10:e2203918. https:\/\/doi.org\/10.1002\/advs.202203918.","journal-title":"Adv Sci (Weinh)"},{"key":"8011_CR145","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/ijo.2024.5615","volume":"64","author":"G Wu","year":"2024","unstructured":"Wu G, Wang D, Xiong F, Wang Q, Liu W, Chen J, et al. The emerging roles of CEACAM6 in human cancer (review). Int J Oncol. 2024;64:27. https:\/\/doi.org\/10.3892\/ijo.2024.5615.","journal-title":"Int J Oncol"},{"key":"8011_CR146","doi-asserted-by":"publisher","first-page":"643669","DOI":"10.3389\/fonc.2021.643669","volume":"11","author":"F An","year":"2021","unstructured":"An F, Zheng C, Zhang G, Zhou L, Wu Y, Hou Z, et al. Carcinoembryonic antigen related cell adhesion molecule 6 promotes carcinogenesis of gastric cancer and anti-CEACAM6 fluorescent probe can diagnose the precancerous lesions. Front Oncol. 2021;11:643669. https:\/\/doi.org\/10.3389\/fonc.2021.643669.","journal-title":"Front Oncol"},{"key":"8011_CR147","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-022-30142-9","volume":"13","author":"PMR Pereira","year":"2022","unstructured":"Pereira PMR, Mandleywala K, Monette S, Lumish M, Tully KM, Panikar SS, et al. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun. 2022;13:2526. https:\/\/doi.org\/10.1038\/s41467-022-30142-9.","journal-title":"Nat Commun"},{"key":"8011_CR148","doi-asserted-by":"publisher","first-page":"35884","DOI":"10.1021\/acsomega.3c03614","volume":"8","author":"S Surendra Panikar","year":"2023","unstructured":"Surendra Panikar S, Shmuel S, Lewis JS, Pereira PMR. PET and optical imaging of caveolin-1 in gastric tumors. ACS Omega. 2023;8:35884\u201392. https:\/\/doi.org\/10.1021\/acsomega.3c03614.","journal-title":"ACS Omega"},{"key":"8011_CR149","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s10120-024-01568-5","volume":"28","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zheng M, Cai Y, Kamara S, Chen J, Zhu S, et al. Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer. Gastric Cancer. 2025;28:174\u201386. https:\/\/doi.org\/10.1007\/s10120-024-01568-5.","journal-title":"Gastric Cancer"},{"key":"8011_CR150","doi-asserted-by":"publisher","first-page":"9838","DOI":"10.3390\/ijms26209838","volume":"26","author":"B Tha Shrestha","year":"2025","unstructured":"Tha Shrestha B, Feng Y, Lad A, Bates A, Chen J, Brown K, et al. The role of cadherin 17 (CDH17) in cancer progression via wnt\/\u03b2-catenin signalling pathway: A systematic review and meta-analysis. IJMS. 2025;26:9838. https:\/\/doi.org\/10.3390\/ijms26209838.","journal-title":"IJMS"},{"key":"8011_CR151","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/acs.molpharmaceut.4c01285","volume":"22","author":"C Mao","year":"2025","unstructured":"Mao C, Li S, Fan R, Zhang J, Fan X, Shentu Z, et al. Development and characterization of the [177Lu]lu-labeled anti-CDH17 nanobody derivative for radioimmunotherapy in the gastric cancer xenograft model. Mol Pharm. 2025;22:2077\u201387. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01285.","journal-title":"Mol Pharm"},{"key":"8011_CR152","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia Y, Huang C, Zhong M, Zhong H, Ruan R, Xiong J, et al. Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion. Cell Commun Signal. 2025;23:46. https:\/\/doi.org\/10.1186\/s12964-025-02033-1.","journal-title":"Cell Commun Signal"},{"key":"8011_CR153","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1039\/d2qi00442a","volume":"9","author":"A Guillou","year":"2022","unstructured":"Guillou A, Ouadi A, Holland JP. Heptadentate chelates for 89Zr-radiolabelling of monoclonal antibodies. Inorg Chem Front. 2022;9:3071\u201381. https:\/\/doi.org\/10.1039\/d2qi00442a.","journal-title":"Inorg Chem Front"},{"key":"8011_CR154","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/acs.molpharmaceut.3c00041","volume":"20","author":"D Shi","year":"2023","unstructured":"Shi D, Xu Z, Cheng Y, Lin Q, Si Z, Fu W, et al. 124I-labeled immuno-PET targeting hTREM2 for the diagnosis of gastric carcinoma. Mol Pharm. 2023;20:2235\u201344. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00041.","journal-title":"Mol Pharm"},{"key":"8011_CR155","doi-asserted-by":"publisher","first-page":"740111","DOI":"10.3389\/fonc.2021.740111","volume":"11","author":"B Xue","year":"2021","unstructured":"Xue B, Jiang J, Chen L, Wu S, Zheng X, Zheng X, et al. Development and validation of a radiomics model based on 18F-FDG PET of primary gastric cancer for predicting peritoneal metastasis. Front Oncol. 2021;11:740111. https:\/\/doi.org\/10.3389\/fonc.2021.740111.","journal-title":"Front Oncol"},{"key":"8011_CR156","doi-asserted-by":"publisher","unstructured":"Hasanabadi S, Cheraghi M, Manesh HB, Bayat M, Karam MB, Corsi A et al. Per-lesion radiomics analysis of 68Ga-DOTA FAPI-46 and 18F-FDG PET\/CT in non-small cell lung cancer: A pilot study [Internet]. arXiv; 2025 [cited 2026 Feb 12]. https:\/\/doi.org\/10.48550\/arXiv.2511.08812","DOI":"10.48550\/arXiv.2511.08812"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08011-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:49:39Z","timestamp":1777589379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08011-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8011"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08011-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review does not report any new studies involving human participants or animals. All studies discussed herein were previously published and were conducted in accordance with relevant institutional and national ethical standards, as well as the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"All authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"616"}}